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Background: Frontotemporal lobar degeneration (FTLD) is the second most common cause of dementia in
individuals under 65 years old and manifests as alterations in behavior, personality, or language secondary to
degeneration of the frontal and/or temporal lobes. FTLD-TDP, the largest neuropathological subset of FTLD, is
characterized by hyperphosphorylated, ubiquitinated TAR DNA-binding protein 43 (TDP-43) inclusions. Mutations in
progranulin (GRN), a neuroprotective growth factor, are one of the most common Mendelian genetic causes of
FTLD-TDP. Moreover, a recent genome-wide association study (GWAS) identified multiple SNPs within the
uncharacterized gene TMEM106B that significantly associated with FTLD-TDP, suggesting that TMEM106B genotype
confers risk for FTLD-TDP. Indeed, TMEM106B expression levels, which correlate with TMEM106B genotype, may play
a role in the pathogenesis of disease.
Results: Since little is known about TMEM106B and its expression in human brain, we performed
immunohistochemical studies of TMEM106B in postmortem human brain samples from normal individuals,
FTLD-TDP individuals with and without GRN mutations, and individuals with other neurodegenerative diseases. We
find that TMEM106B protein is cytoplasmically expressed in both histopathologically affected and unaffected areas
of the brain by neurons, glia, and endothelial cells/pericytes. Furthermore, we demonstrate that TMEM106B
expression may differ among neuronal subtypes. Finally, we show that TMEM106B neuronal expression is
significantly more disorganized in FTLD-TDP cases with GRN mutations, compared to normal and disease controls,
including FTLD-TDP cases without GRN mutations.
Conclusions: Our data provide an initial neuropathological characterization of the newly discovered FTLD-TDP
-associated protein TMEM106B. In addition, we demonstrate that FTLD-TDP cases with GRN mutations exhibit a loss
of neuronal TMEM106B subcellular localization, adding to evidence that TMEM106B and progranulin may be
pathophysiologically linked in FTLD-TDP.
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Frontotemporal lobar degeneration (FTLD) is a fatal
neurodegenerative disease characterized by selective de-
generation of the frontal and temporal lobes [1,2]. Func-
tionally, patients often present with alterations in behavior,
personality and language, rather than with memory im-
pairment as seen in patients with Alzheimer’s disease
[3-5]. FTLD is neuropathologically classified into two
major subtypes: FTLD-tau and FTLD-TDP [4,6]. FTLD-
tau cases are characterized by abnormal accumulations of
the microtubule-associated protein tau in neurons and
glia, while FTLD-TDP cases harbor neuronal inclusions of
ubiquitinated, hyperphosphorylated TAR DNA-binding
protein 43 (TDP-43) [7,8].
FTLD-TDP comprises approximately 50% of clinical
FTLD [9]. Mutations in the progranulin gene (GRN),
which codes for a growth factor with neuroprotective ef-
fects [10,11] account for ~10% of FTLD-TDP [12-14]. The
majority of these autosomal dominant mutations result in
premature termination codons and thus progranulin
haploinsufficiency [14,15]. In addition, expansions in the
C9orf72 gene have recently been shown to be an import-
ant Mendelian cause of FTLD-TDP [16,17]. However, the
majority of FTLD-TDP cases do not show clear Mendelian
patterns of inheritance.
In order to identify additional genetic risk factors, we
previously performed a genome-wide association study
(GWAS) and identified multiple SNPs within the
uncharacterized gene TMEM106B that significantly as-
sociated with FTLD-TDP (odds ratio 1.6, p = 1.08 × 10-11
for top SNP rs1990622) [18]. This association has been
replicated in a clinically diagnosed cohort of patients
[19] and was most recently replicated in a cohort of
FTLD-TDP patients carrying GRN mutations [20], al-
though other investigators have not replicated the asso-
ciation [21]. We and others have investigated the
physiological [22-24] and pathophysiological [25-28]
function of TMEM106B. TMEM106B genetic variants
may confer increased disease risk by increasing levels of
TMEM106B expression, since mRNA expression levels of
TMEM106B are >2.5-fold higher in FTLD-TDP cases vs.
controls [18], and are particularly increased in FTLD-TDP
cases with GRN mutations [24]. Moreover, TMEM106B
risk genotypes have been associated with higher levels of
TMEM106B expression in lymphoblastoid cell lines [29]
and in human brain tissue [18,24], suggesting that the var-
iants found by GWAS tag a cis-acting mechanism for
regulating TMEM106B expression. One possible mechan-
ism was recently identified by Nicholson et al. [20], who
demonstrated that differential isoforms at the coding SNP
rs3173615 (p.T185S), which is in linkage disequilibrium
with the GWAS SNP rs1990622, result in different rates
of protein degradation. The risk (T185) isoform of
TMEM106B is degraded less quickly than the protective(S185) form of TMEM106B. Together, these data suggest
that TMEM106B variants resulting in higher levels of
TMEM106B protein may increase disease risk.
Evidence further suggests that TMEM106B risk geno-
types/increased TMEM106B expression may modulate
disease risk by affecting progranulin pathways. For ex-
ample, TMEM106B risk genotypes have been associated
with decreased plasma progranulin levels [26], and sig-
nificantly earlier onset of disease in GRN mutation car-
riers [27]. Moreover, TMEM106B, which localizes to late
endosomes / lysosomes in multiple cell lines and in
mouse primary cortical and hippocampal neurons
[22-24], has been shown to co-localize with progranulin
[20,23,24]. Intriguingly, expression of TMEM106B as
compared to control results in increased intracellular
progranulin [20,23,24], and changes progranulin’s appar-
ent subcellular compartmentalization as visualized by
immunofluorescence microscopy [24].
While studies to date have established TMEM106B as
an important risk factor for FTLD-TDP and implicated
TMEM106B in progranulin pathways, many basic features
of this protein -- including its expression patterns in hu-
man brain -- are largely unknown. To further characterize
this novel disease-related protein, we investigate here the
distribution and appearance of TMEM106B in postmor-
tem human brain samples from normal and disease con-
trols, FTLD-TDP individuals with GRN mutations (GRN
(+) FTLD-TDP), and FTLD-TDP individuals without GRN
mutations (GRN (−) FTLD-TDP).
Results
TMEM106B expression by cell type in normal human
brain tissue
We began by characterizing TMEM106B expression in
normal human brain tissue. As shown in Figure 1, we
found that TMEM106B is expressed in neurons, glia,
and in cells surrounding blood vessels in frontal and oc-
cipital cortical samples from normal controls. Specific-
ally, TMEM106B is a cytoplasmic protein that assumes a
polarized, perikaryal distribution in neurons (Figure 1a).
Glial cells also demonstrate TMEM106B in an asymmet-
ric, polarized pattern within the cytoplasm (Figure 1b).
Finally, occasional robust TMEM106B immunoreactivity
was observed peri-vascularly, in endothelial cells or
pericytes (Figure 1c). TMEM106B immunoreactivity in
neurons and glia was observed throughout all layers of
neocortex, with prominent expression in the pyramidal
neurons of layers 3–5 (Figure 2a).
TMEM106B expression by brain region in normal human
brain tissue
We next evaluated whether TMEM106B expression and
appearance varies by brain region. In occipital cortex, a
region of the brain relatively spared from TDP-43
Figure 1 TMEM106B expression in neurons, glial and endothelial cells or pericytes in cortical specimens from normal controls.
TMEM106B is normally cytoplasmically expressed in neurons (a), glia (b), and endothelial cells or pericytes (c). (a) Neuronal staining in cortices
from normal human controls demonstrated a perikaryal, polarized cytoplasmic distribution mainly in the cell body and variably extending into
processes. (b) Glial distribution of TMEM106B similarly demonstrated an asymmetric cytoplasmic distribution. (c) A subset of endothelial cells or
pericytes demonstrated intense cytoplasmic expression of TMEM106B. Sections were stained with the anti-TMEM106B polyclonal antibody N2077
[24]. Scale bar represents 50 um.
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cytoplasmic pattern of TMEM106B expression when
compared to neurons and glia of frontal cortex, a brain
region which typically displays a heavy burden of TDP-
43 pathology (Figure 2b and c) [30].
In the hippocampus, however, whereas TMEM106B ex-
pression was clearly seen in the pyramidal neurons of
Ammon’s horn (Figure 2d), no significant staining of the
dentate gyrus was observed (Figure 2e), suggesting neur-
onal subtype specificity of TMEM106B expression. Lenti-
form nucleus sections from normal controls showed
minimal TMEM106B expression (Figure 2f); additionally,
neurons of the nucleus basalis of Meynert had little to no
staining (not pictured). In cerebellar sections, Purkinje cells
demonstrated little TMEM106B expression (Figure 2g),
and neurons of the granular layer did not stain for
TMEM106B (Figure 2g). In contrast, neurons of the deep
cerebellar nuclei showed diffuse TMEM106B immunoreac-
tivity with varying degrees of granularity (Figure 2h).
In summary, we observed variability in TMEM106B ex-
pression by neuronal subtype. However, TMEM106B ex-
pression did not demonstrate obvious differences in
neocortical regions vulnerable to neurodegeneration, com-
pared to those relatively resilient to neurodegeneration, in
FTLD-TDP.
TMEM106B expression in FTLD-TDP brain
Given the putative role of TMEM106B in FTLD-TDP,
we stained frontal cortex, occipital cortex, cerebellar,
hippocampal, and lentiform nucleus sections from indi-
viduals with GRN (+) FLTD-TDP, GRN (−) FTLD-TDP,
and normal controls. In addition, we included FTLD-tau,
and Alzheimer’s disease (AD) brain samples as non-
FTLD-TDP disease controls.
While FTLD-TDP is characterized by neuronal cyto-
plasmic inclusions (NCI) and (depending on histological
subtype) neuronal intranuclear inclusions (NII) of TDP-43, these TDP-43-containing pathological inclusions did
not contain TMEM106B. Furthermore, TMEM106B did
not appear to form pathological inclusions of any type in
the eleven FTLD-TDP cases investigated here. Compar-
ing normal and disease-affected specimens, however,
we noted greater variability in the appearance of
TMEM106B cytoplasmic staining among the disease
cases. Specifically, in neurons, cytoplasmic TMEM106B
ranged from an organized perikaryal distribution to a
disordered phenotype in which TMEM106B was
expressed diffusely throughout the cell body and even
extended into neuronal processes.
To further characterize these differences, we semi-
quantitatively rated specimens based on their degree of
apparent TMEM106B disorganization and loss of subcel-
lular localization using an ordinal scale ranging from 0
(most polarized/organized) to 3 (most diffuse/disorga-
nized). Specifically, two individuals blinded to disease
status rated 29 frontal cortex samples for patterns of
TMEM106B staining, as described in Figure 3a (normal
controls n = 7; AD n = 5; FTLD-tau n = 6, GRN (+)
FTLD-TDP n = 6, GRN (−) FTLD-TDP n = 5).
Inter-rater reliability was moderately high (weighted
kappa = 0.44). Moreover, as shown in Figure 3b, GRN (+)
FTLD-TDP cases showed the most disorganized patterns
of TMEM106B staining, with an average score (2.125)
that was significantly greater when compared to all other
cases (Mann–Whitney test, p = 0.005). Moreover, while
TMEM106B expression rarely extended into neuronal
processes for normal controls, FTLD-tau, AD, or GRN
(−) FTLD-TDP cases, in every GRN (+) FTLD-TDP case,
we observed TMEM106B expression extending into
neuronal processes even in otherwise healthy-appearing
neurons. Staining sections with a second TMEM106B
antibody demonstrated similar results (Figure 4). Fur-
thermore, TDP-43 pathology did not differ significantly
between GRN (+) FTLD-TDP and GRN (−) FTLD-TDP
Figure 2 TMEM106B protein expression in brain tissue from normal controls. TMEM106B protein expression is found throughout all layers
of neocortex. Frontal cortex is shown in (a). TMEM106B neuronal and glial staining pattern is similar in both histopathologically affected areas of
the brain (b, frontal cortex) and in areas of the brain that are relatively spared of TDP-43 pathology (c, occipital cortex). In the hippocampus, the
pyramidal neurons of Ammon’s horn show positive TMEM106B immunoreactivity (d), whereas those of the dentate gyrus do not (e). Lentiform
nucleus sections demonstrated very rare neuronal staining (f). There was minimal staining of the Purkinje cells of the cerebellum; rarely, cells
demonstrated a cytoplasmic, granular staining, as highlighted in (g). Neurons of the deep cerebellar nuclei demonstrated diffuse cytoplasmic
TMEM106B (h). Sections were stained with the anti-TMEM106B polyclonal antibody N2077 [24]. Scale bar represents 50 um.
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used in this study were matched by histopathological
subtype to GRN (+) FTLD-TDP cases; all were FTLD-
TDP Type A cases [31].
Thus, TMEM106B expression differs significantly in
frontal cortex neurons of GRN (+) FTLD-TDP brain.
Specifically, in this genetic subtype, TMEM106B is dif-
fusely expressed throughout the neuronal cytoplasm,
with frequent extension into neuronal processes.
Discussion
In this study, we have provided an initial characterization
of TMEM106B protein expression in normal, GRN (−)
FTLD-TDP, and GRN (+) FTLD-TDP human brain, as
well as other neurodegenerative disease controls. We find
that TMEM106B is normally expressed in the cytoplasmof neurons, glia, and peri-vascular endothelial cells or
pericytes, although there may be differences based
on neuronal subtype. Unlike many neurodegenerative
disease-related proteins, TMEM106B does not form
pathological inclusions in diseased brain. Instead, we show
that neurons in GRN (+) FTLD-TDP cases exhibit more
disorganized cytoplasmic TMEM106B expression than
normal or disease controls. Specifically, TMEM106B ex-
pression in these cases demonstrates loss of polarity as
well as subcellular compartmentalization.
In immortalized cell lines and primary cortical neu-
rons, we and others have shown that TMEM106B is lo-
calized to endosomes or lysosomes [20,22-24]. We note
that the pattern of TMEM106B staining in normal hu-
man brain tissue is compatible with this subcellular
localization as well, although further studies using
Figure 3 Scoring of neuronal TMEM106B protein expression. (a) Scoring schema used to grade severity of disorganization of neuronal
TMEM106B expression. Scores of 0 were assigned to sections in which almost all neurons displayed cytoplasmic TMEM106B expression with a
vesicular pattern exhibiting a polarized quality. Nuclear boundaries were clear. Scores of 1 were assigned to sections in which a sizeable number
of neurons displayed more diffuse TMEM106B staining dispersed more widely in the cytoplasm, but still delimited to the soma. Polarity was still
usually maintained. Scores of 2 were assigned to sections in which most neurons recapitulated the characteristics of a score of 1. However, these
sections also contained rare, non-degenerating neurons which displayed highly disorganized and diffuse TMEM106B staining throughout the
cytoplasm with extension into processes. Scores of 3 were assigned to sections in which numerous neurons displayed highly disorganized and
diffuse TMEM106B staining, with extension into processes. Scale bar represents 30 um. (b) Shown is the average scoring of the degree of diffuse
neuronal TMEM106B expression by two independent, blinded scorers for N2077-stained human frontal cortical samples. Normal cases n = 7;
Alzheimer’s disease n = 5; FTLD-tau n = 6, GRN (−) FTLD-TDP n = 5, GRN (+) FTLD-TDP n = 6. The colors in the dot plot correspond to the groups
delineated in the bar graph. Weighted kappa = 0.44. GRN (+) FTLD-TDP cases demonstrated more disorganized patterns of TMEM106B expression
(p = 0.005 for Mann–Whitney test).
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definitively demonstrate this.
The present finding that GRN (+) FTLD-TDP cases ex-
hibit significantly different patterns of TMEM106B ex-
pression is intriguing. It is unlikely that this finding is due
to neurodegeneration alone, since disease controls (FTLD-
tau, AD) showed the least disorganization. Moreover,
GRN (−) FTLD-TDP cases with similar patterns of TDP-
43 pathology did not demonstrate TMEM106B expression
extending into neuronal processes, suggesting that this ef-
fect is specific to the GRN (+) FTLD-TDP genetic subtype.
We have previously shown that GRN (+) FTLD-TDP has a
distinct global mRNA expression profile [32], suggesting
that distinct pathophysiological mechanisms may exist in
this molecularly defined subgroup. Moreover, recent evi-
dence implicates TMEM106B in GRN (+) FTLD-TDP
pathways. Specifically, we have previously shown that
TMEM106B may be expressed at higher levels in GRN (+)
FTLD-TDP brain [24], which is consistent with the histo-
pathological pattern described here of TMEM106B ex-
pression throughout the neuronal cytoplasm in these
genetic cases. Secondly, TMEM106B may act as a geneticmodifier among GRN mutation carriers, influencing age at
disease onset and levels of circulating progranulin [26,27].
Finally, we and others have recently demonstrated that
over-expression of TMEM106B affects endo-lysosomal
appearance and function as well as the distribution of
progranulin in intracellular and extracellular compart-
ments [20,23,24].
In this context, the current study provides further evi-
dence of a relationship between TMEM106B and
progranulin, although the directionality of this relationship
is unclear. The observation that GRN mutation carriers
exhibit disordered TMEM106B expression suggests that
abnormalities in progranulin can influence TMEM106B
expression patterns, whereas the TMEM106B over-
expression studies suggest that TMEM106B levels affect
progranulin. One possibility to reconcile these findings is
that a feedback loop exists between TMEM106B and
progranulin in the pathogenesis of FTLD-TDP. Additional
studies to investigate this possibility would be a valuable
addition to the data presented here.
Our current study has several limitations. First, our
sample size of 29 cases may not adequately represent the
Figure 4 TMEM106B expression is more disorganized in neurons from GRN (+) FTLD-TDP cases, despite comparable levels of TDP-43
pathology. Representative frontal cortical sections from a normal control (a), GRN (−) FTLD-TDP (b), and GRN (+) FTLD-TDP (c). Both the N2077
antibody (top row) [24] and a different polyclonal antibody (middle row) raised against the N-terminus (amino acids 1–96) of TMEM106B [23]
show similar patterns of immunoreactivity on serial sections from the same cases. GRN (+) FTLD-TDP cases showed more disorganized TMEM106B
expression than GRN (−) FTLD-TDP cases, despite similar degrees of TDP-43 pathology, as indicated by staining against pathological,
phosphorylated forms of TDP-43 (bottom row). Scale bar represents 50 um.
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a larger sample size. However, even with this small sam-
ple size, we were able to detect a significant difference in
TMEM106B expression in GRN (+) FTLD-TDP. Second,
the use of postmortem brain samples limits our ability
to interpret the current finding, since non-specific ef-
fects due to postmortem interval, disease duration, cell
loss and gliosis could confound our results. Finally, sam-
ples used here were not strictly age- and gender-matched
among groups. However, the GRN (+) FTLD-TDP group
did not differ significantly from the other groups in
these respects (t-test p = 0.612 for age comparison, chi-
square p = 0.775 for sex comparison), decreasing the
possibility that these demographic variables may ac-
count for the observed effect.Conclusions
In conclusion, we have provided the first histological
characterization of TMEM106B expression in multiple re-
gions of pathological and normal human brain. Our data
add to the growing body of evidence that TMEM106B and
progranulin may be linked mechanistically in the patho-
genesis of FTLD-TDP. Further characterization of this
new FTLD-TDP risk factor, as well as its interactions with
progranulin, may open up new avenues for the develop-
ment of disease-modifying therapies.Methods
Brain samples
Human postmortem brain samples were obtained from
the University of Pennsylvania Center for Neurodegener-
ative Disease Brain Bank under IRB approval. These
comprised samples from normal individuals (n = 7), as
well as individuals with FTLD-TDP (n = 11), FTLD-tau
(n = 6), and Alzheimer’s disease (AD, n = 5). Regions
sampled included midfrontal cortex, occipital cortex,
cerebellum, lentiform nucleus, and hippocampus. See
Additional file 1: Table S1 for a detailed list of cases.
Histopathological subtyping for FTLD-TDP was
performed according to established criteria [31]. Genetic
testing for C9orf72 expansions, GRN mutations, and
MAPT mutations was performed as previously described
[33,34]. One FTLD-TDP case was found to harbor a
C9orf72 expansion -- TMEM106B expression in this
case did not appear atypical for the GRN (−) FTLD-TDP
group. In addition, 6 FTLD-TDP cases had GRN muta-
tions, and no cases had MAPT mutations.
Immunohistochemistry
Formalin-fixed, paraffin-embedded 6 μm sections from
various brain regions were cleared in a descending etha-
nol series then blocked with 3% H2O2/MeOH for 30
minutes. After washing, sections were immersed in Anti-
gen Unmasking Solution (Vectashield) and microwaved
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power. Slides were allowed to cool to room temperature,
then washed with 0.1 M Tris buffer, pH 7.6 (Tris) for
five minutes. Sections were blocked in Tris + 2% FBS,
pH 7.6 (Tris/FBS) for five minutes, before overnight in-
cubation at 4°C with primary antibody (see Additional
file 1: Table S2 for antibody conditions). Specimens were
immersed in Tris buffer x 5 minutes, followed by Tris/
FBS x 5 minutes. Biotinylated goat anti-rabbit secondary
antibody (Vectashield) was applied, and samples were
incubated at room temperature in a humidified chamber
for one hour. Samples were washed briefly in Tris.
VECTASTAIN AB solution (Vector Labs) made up in
Tris/FBS was applied to the samples and incubated for
one hour at room temperature. Slides were then incu-
bated with ImmPACT DAB solution (Vector Labs) for
2–8 minutes until desired stain intensity was achieved.
Specimens were rinsed briefly with Tris, followed by
dH2O and then counterstained with Harris’ hematoxylin
(Thermo-Shandon) for 10–30 seconds. Slides were
washed in running tap water for 5 minutes. Coverslips
were sealed with Cytoseal (Thermo Scientific) and slides
were allowed to dry for at least one hour.
TMEM106B antibodies used in this manuscript were
N2077, a previously validated [24] polyclonal rabbit anti-
body directed at amino acids 4–19 of TMEM106B
(a peptide sequence specific to TMEM106B). Additional
data supporting the specificity of N2077 for TMEM106B
are provided in Additional file 1: Figure S1. A second
polyclonal rabbit antibody raised against amino acids
1–96 of TMEM106B was used to verify results; this sec-
ond antibody has been previously validated as well [23].Semi-quantitative assessment of TMEM106B expression
Two independent, blinded observers (MML and ACP)
scored stained specimens from normal controls (n = 7),
as well as from patients with Alzheimer’s disease (n = 5),
FTLD-tau (n = 6), GRN (+) FTLD-TDP (n = 6), and GRN
(−) FTLD-TDP (n = 5), assessing for the nature and de-
gree of neuronal staining. Specimens were assigned
scores of 0–3 based on an ordinal scale representing in-
creasing loss of subcellular localization and polarity.
Representative images and scoring criteria are described
in the Results section.Additional file
Additional file 1: Table S1. Characteristics of cases and brain regions
evaluated for TMEM106B expression. Table S2. Antibodies and conditions
used for immunohistochemical staining. Figure S1. Validation of
TMEM106B antibody.
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